Month: January 2018

Genomics England and Inserm partnership strengthens UK-French cooperation in genomic medicine

As part of the UK-French summit held in Sandhurst yesterday (18 January 2018), the UK and French Governments have announced enhanced cooperation between Genomics England and the French ‘Médecine Génomique 2025’ project.

The Strategic Genomic Medicine Partnership marks a strengthening of the existing relationship between Genomics England and the French National Institute of Health and Medical Research (Inserm). Formalising the agreement, senior representatives of both organisations signed a letter of intent for a Memorandum of Understanding (MoU).

The UK and France will combine our shared national attributes by co-funding shared analysis of new technologies to accelerate genomic medicine and research collaboration, ultimately improving the care of patients with cancer and rare diseases.

L-R: Matt Hancock MP, Sir John Chisholm, Yves Levy and Brune Poirson, at the UK-France Summit 2018.

Genomics England Executive Chairman, Sir John Chisholm, said:
“The Strategic Partnership announced today sees two global pioneers combining know-how to realise the full potential of genomic medicine. Genomics England and Inserm will work together more closely than ever before – signalling our joint ambition to lead the world in genomic discovery, develop more effective treatments and drive economic growth in the sector.”

Genomics England Chief Scientist, Professor Mark Caulfield, said:
“Today’s agreement ensures that the UK and France continue to set the pace in global genomics. Both of our nations are on the verge of introducing genomic medicine into mainstream health services and this enhanced cooperation will allow us to set new and lasting global standards, share learning and, ultimately, deliver the best possible care to our patients.”

Genomics England adopts Edico Genome’s DRAGEN Bio-IT Platform

Genomics England adopts Edico Genome’s DRAGEN Bio-IT Platform to increase accuracy, consistency of next-generation sequencing analysis

Today (8 January 2018) at the annual J.P. Morgan Healthcare Conference, Edico Genome and Genomics England announced a new partnership to strengthen the accuracy and consistency of next-generation sequencing data analysis in Genomics England’s Rare Disease Pilot.

The partnership will further support Genomics England’s 2018 initiative to making next-generation sequencing (NGS) the standard of care across the UK’s National Health Service in 2018. Specifically, the partnership will focus on the analysis pipeline − improving alignment and variant calling in whole genome sequencing data. Genomics England selected DRAGEN for its industry leading accuracy and speed, enabling the organisation to accelerate analysis of large clinical genomic datasets.

“Working with Edico Genome, Genomics England moves one step closer to reaching genomic medicine’s full potential, and improving the efficiency of whole genome analysis to help diagnose rare diseases,” said Joanne Hackett, chief commercial officer at Genomics England. “This partnership demonstrates our commitment to harnessing the most innovative technologies in the world to maximise patient benefit.”

Genomics England is currently using DRAGEN to re-process 5,000 whole human genomes from individuals with rare diseases. These genomes were originally mapped and aligned on reference genome GRCh37, but an updated human reference genome has since been released, GRCh38, which offers increased accuracy and consistency of results. These reprocessed datasets will be provided to pharma and industry partners for additional analysis through the Discovery Forum, a platform for collaboration and engagement between Genomics England, industry partners, academia, the NHS, and the wider UK genomics landscape. In conjunction with the announcement, Edico Genome has joined Discovery Forum.

“Genomics England is truly paving the way for the widespread integration of whole-genome sequencing on a population scale, bringing the future of personalized medicine into the now for individuals across the U.K.,” said Pieter van Rooyen, Ph.D., president and chief executive officer at Edico Genome. “Our bioinformatics and engineering teams are committed to pushing the envelope in terms of accuracy, sensitivity, speeds and scalability to ensure the highest level of personalized care can be delivered in a timely, cost effective and economical manner. We are honored to be able to assist in such an important undertaking – helping diagnose rare diseases — and look forward to bringing further optimizations and new pipelines to customers in 2018.”

By leveraging field programmable gate arrays (FPGAs), DRAGEN provides outputs almost instantaneously and processes clinical grade genomic data at record-breaking speeds. To ensure precise results, all DRAGEN pipelines feature validated algorithms for enhanced accuracy. DRAGEN can be implemented onsite, in the Cloud, or through a blended hybrid-cloud solution.

Edico Genome